



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: KAFRISSEN et al.

Serial No.: 09/677,976

Art Unit: 1616

Filed

: October 2, 2000

Examiner: CHOI, Frank I.

For

: PHARMACEUTICAL METHODS OF DELIVERING FOLIC ACID

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Mail Stop Amendment, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 27, 2005
(Date of Deposit)

Joseph S. Kentoffio
(Name of applicant, assignee, or Registered Representative)

/Joseph S. Kentoffio, Reg. No. 33,189/

(Signature)

October 27, 2005

(Date of Signature)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Washington, D.C. 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on January 12, 2001 and April 1, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

\square In accordance with \$1.97(b), since this information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
\$1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under \$1.114, no additional
fee is required.
\square In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with \square the
first or _second After Final Submission, therefore:
<pre>Statement in Accordance with \$1.97(e)</pre>
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in \$1.17(p).

In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

		Statement in Accordance with \$1.97(e) (attached); or
		Please charge Deposit Account No. 10- $0750/ORT1316/JSK$ the fee of $$180.00$ as set forth in $$1.17(p)$.
Di cal caux		coordance with \$1.97(d), this Information
		ement is being filed after the mailing date of Action under \$1.113 or a Notice of Allowance
		out before the payment of the Issue Fee.
		ereby petition(s) for consideration of this
		sclosure Statement. Included are: Statement in
		n §1.97(e) as set forth below and the fee of
\$180.00 a	s set	forth in \$1.17(p).
☐ 1449 are 6	-	es of references listed on the attached Form PTO- sed herewith EXCEPT THAT:
☐ 1449 are 0	-	
1449 are (-	sed herewith EXCEPT THAT:
☐ 1449 are (-	sed herewith EXCEPT THAT: In view of the voluminous nature of references
☐ 1449 are (-	In view of the voluminous nature of references [list as appropriate], and the likelihood that
☐ 1449 are (-	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner,
☐ 1449 are (-	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
1449 are	-	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. If any of the foregoing publications are not
□ 1449 are 6	enclos	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's

igtieq There are no listed references which are not in the
English language.
The relevance of those listed references which are
not in the English language is as follows:
☐ Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Copies of the references listed on the search
report(s) are included except for those previously cited in an
IDS mailed .
Attached are the following non-published pending
patent applications which may be deemed relevant, which are
listed on the attached Submission Under MPEP 609 D.
Please charge any deficiency or credit any overpayment to
Deposit Account No. 10-0750/ORT1316/JSK. This form is
submitted in triplicate.
Respectfully submitted,
/Joseph S. Kentoffio/
Joseph S. Kentoffio
Reg. No. 33,189 Attorney for Applicants
Johnson & Johnson Plaza One Johnson & Johnson Plaza

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-3711
DATED: October 27, 2005
Customer No. 000027777

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

a collection of information unless it displays a valid OMB control number.					
Application Number	09/677,976				
Filing Date	10/02/2000				
First Named Inventor	Michael E. Kafrissen				
Group Art Unit	1616				
Examiner Name	Frank I. Choi				
Attorney Docket Number	ORT-1316-USNP				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's Initials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SCHUBRING, C.: "Hormonal Contraception in the Medical Practice", Med. Welt (39, No. 36, 1040-49, 1988)	X
_			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.